Sato, Shoichiro http://orcid.org/0000-0001-8551-434X
Hatakeyama, Naohisa
Fujikoshi, Shinji
Katayama, Sadao
Katagiri, Hideaki
Sims, John R.
Funding for this research was provided by:
Eli Lilly Japan
Article History
Received: 12 December 2023
Accepted: 14 March 2024
First Online: 6 April 2024
Declaration
:
: Shoichiro Sato, Naohisa Hatakeyama, Hideaki Katagiri, and Shinji Fujikoshi are employees of Eli Lilly Japan K.K. and minor shareholders in Eli Lilly and Company. Sadao Katayama was an investigator in the TRAILBLAZER-ALZ 2 trial and has received lecture fees from Eli Lilly Japan K.K., Eisai Co., Ltd., and Kowa Pharmaceutical Industry Co., Ltd. John Sims is an employee of and minor shareholder in Eli Lilly and Company.
: This trial was conducted according to the Declaration of Helsinki, the International Council for Harmonisation Guideline for Good Clinical Practice, and local regulatory requirements. The protocol was approved by ethics review boards at each study site. Participants and their partners provided written informed consent before any study procedures were conducted. Permission to use the Clinical Dementia Rating Scale and the Alzheimer’s Disease Assessment Scale was obtained from the copyright holders before the start of the study.